NYSE: MDPediatrix Medical Group Inc Stock
$16.97-0.42 (-2.42%)
Updated Oct 31, 2025
MD Price
$16.97
Fair Value Price
N/A
Market Cap
$1.48B
52 Week Low
$11.84
52 Week High
$18.22
P/E
12.95x
P/B
1.77x
P/S
0.63x
PEG
0.91x
Dividend Yield
N/A
Revenue
$1.94B
Earnings
$109.92M
Gross Margin
24.4%
Operating Margin
9.26%
Profit Margin
5.7%
Debt to Equity
1.52
Operating Cash Flow
$245M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MD Overview
Pediatrix Medical Group Incorporated (formerly MEDNAX, Inc.) provides neonatal, maternal-fetal, paediatric cardiology, and related sub-speciality services. It has operations in the U.S. and Puerto Rico through affiliated professional corporations. Pediatrix Medical Group was founded in 1979 and is headquartered in Sunrise, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MD's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
MD
Ranked#3 of 42
Ranked#3 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.87 | A | |
| $9.05 | A | |
| $217.01 | A |
Be the first to know about important MD news, forecast changes, insider trades & much more!
MD News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MD ($16.97) is trading above its intrinsic value of $14.67, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MD is good value based on its earnings relative to its share price (12.95x), compared to the US market average (41.65x)
P/E vs Market Valuation
MD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more MD due diligence checks available for Premium users.
Valuation
MD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.95x
Industry
16.42x
Market
41.65x
MD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.77x
Industry
5.25x
MD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MD price to earnings growth (PEG)
For valuing profitable companies with growth potential
MD is good value based... subscribe to Premium to read more.
PEG Value Valuation
MD's financial health
Profit margin
Revenue
$468.8M
Net Income
$39.3M
Profit Margin
8.4%
MD's Earnings (EBIT) of $179.74M... subscribe to Premium to read more.
Interest Coverage Financials
MD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.1B
Liabilities
$1.3B
Debt to equity
1.52
MD's short-term assets ($613.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MD's long-term liabilities ($927.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$137.2M
Investing
-$7.2M
Financing
-$4.3M
MD's operating cash flow ($244.55M)... subscribe to Premium to read more.
Debt Coverage Financials
MD vs Medical Care Facility Stocks
Pediatrix Medical Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.